NEON — NeonMind Biosciences Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-20.4%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-77.14%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Nov 202130th Nov 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of NeonMind Biosciences EPS forecast chart

Profile Summary

NeonMind Biosciences Inc. is a Canada-based drug development company. The Company is engaged in drug development research into potential therapeutic uses of psychedelic compounds. The Company operate two divisions, a pharmaceutical division, which is engaged in drug development of psychedelic compounds, and a medical services division, which is in the planning stage, to offer drug enhanced psychotherapy services and other mental health treatments. In its pharmaceutical division, the Company has two distinct psilocybin drug development programs targeting obesity. Its lead candidate, NEO-001, employs psilocybin as an agonist at the serotonin 5- HT2A receptor, which is involved in the hallucinogenic effect of psychedelics. The Company's second drug candidate, NEO-002, employs low-dose psilocybin as an agonist at the 5-HT2C receptor, which controls appetite. SRx Health Solutions is its medical services partner.

Directors

    Last Annual
    November 30th, 2020
    Last Interim
    August 31st, 2021
    Incorporated
    January 1st, 1970
    Public Since
    January 1st, 1970
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    ca flag iconCanadian Securities Exchange
    Shares in Issue
    126,866,533

    NEON Share Price Performance

    Similar to NEON

    Picture of Algernon Pharmaceuticals logo

    Algernon Pharmaceuticals

    ca flag iconCanadian Securities Exchange

    Asep Medical Holdings

    ca flag iconCanadian Securities Exchange

    Picture of Avisa Diagnostics logo

    Avisa Diagnostics

    ca flag iconCanadian Securities Exchange

    Picture of BetterLife Pharma logo

    BetterLife Pharma

    ca flag iconCanadian Securities Exchange

    Picture of Biovaxys Technology logo

    Biovaxys Technology

    ca flag iconCanadian Securities Exchange

    FAQ

    Or unlock with your email

    Or unlock with your email